InvestorsHub Logo
Followers 57
Posts 5826
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Wednesday, 04/02/2025 8:02:01 PM

Wednesday, April 02, 2025 8:02:01 PM

Post# of 486779
I expect European approval of blarcamesine later this year. I also expect worldwide stagflation (increased prices and increased unemployment at the same time).

As a Anavex shareholder how do I expect this to affect blarcamesine sales? Alzheimers is a tragic disease which families and healthcare systems have to face around the world. The current standard of care is very ineffective. The Mabs are not only less effective, but also have serious side effects and a high initial cost and costly follow up. Blarcamesine offers real hope to patients and cost savings to families and health care systems!

Blarcamesine offers higher efficacy, greater safety and significant cost savings! I expect sales to flourish in any economic environment!

Anavex will secure very attractive partnerships and enter European, UK, Australian, Canadian and Asian markets very rapidly IMO. The FDA will almost certainly be forced to follow.

Anavex may be a very bright light in a very dismal market!
Bullish
Bullish

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News